Trump Administration Terminations of 151 Advisory Committees Undermine FDA Accountability Mechanisms
Administration terminations of expert advisory committees at FDA and HHS eliminate public records that historically enabled accountability for drug approvals and coverage mandates. Evidence from prior negative votes shows measurable effects on payor behavior and congressional oversight. Statutory fixes are under discussion to restore expertise and transparency requirements.
Next steps include proposed legislation to codify minimum expertise thresholds and mandatory public voting for all committees reviewing preventive services or vaccines. Absent such reforms, the 2027 cycle of USPSTF recommendations on cancer screening coverage faces heightened legal challenge risk. Regulators must demonstrate how internal reviews substitute for the evidentiary trail advisory committees previously supplied.
FDA: Number of standing advisory committee meetings for new molecular entities will remain below 15 in calendar year 2027, a threshold crossed only once since 2010.
Sources (3)
- [1]Primary Source(https://www.statnews.com/2026/10/30/scientific-expert-advisory-committees-fda-hhs-congress/)
- [2]Supporting Source(https://jamanetwork.com/journals/jama/article-abstract/2801234)
- [3]Supporting Source(https://www.healthaffairs.org/doi/10.1377/hlthaff.2023.01422)